ZFIN is incorporating published figure images and captions as part of an ongoing project. Figures from some publications have not yet been curated, or are not available for display because of copyright restrictions.

Localisation of gpr139 mRNA expression in the brain of zebrafish. In situ hybridisation shows expression of gpr139 mRNA in the ventral habenula (vHb) (A, B). Double labelling of gpr139 mRNA (C, F) with Kiss1 (D) or GPR151(G) immunofluorescence further confirmed specific expression of gpr139 mRNA in the vHb (E) but not in the dorsal habenula (dHb) (H). In the vHb, GPR151-immunoreactive neuropil structure is also seen, which are derived from the dHb (H, asterisks). In the hindbrain region, no expression of gpr139 mRNA was detected in the locus coeruleus (I–K). The dotted box indicates the location for the inset in the panel I. HB habenula; VT ventral thalamus; OT optic tectum; OC optic chiasma; dHb dorsal habenula; vHb ventral habenula; LC locus coeruleus; TS torus semicircularis; CCe cerebellar corpus; NLV nucleus lateralis valvulae; GC central gray; MLF nucleus of the medial longitudinal fascicle; NI nucleus isthmi; LLF lateral longitudinal fascicle; SRF superior reticular formation; SR superior raphe nucleus; TTB tecto-bulbar tract; DIL, diffuse nucleus of inferior lobe. Scale bars: (A, F–H), 100 µm; (B) inset of (I), 50 µm; (C–E), 20 µm; (I, J), 200 µm.

Effect of GPR139 agonist (JNJ63533054) on alarm substance-induced fear response. (A) Representative side-view video tracking of swimming behaviour at 30 min after administration of GPR139 agonist (b, 0.1 µg/g; c, 1 µg/g; d, 10 µg/g body weight, BW) and subsequent alarm substance (AS) administration. However, there were no significant differences in AS-induced fear responses including the total time spent (P = 0.4789, B), total freezing time (P = 0.6826, C), total distance swam (P = 0.7077, D), and swimming velocity (P = 0.6975, E) at the bottom of a tank among GPR139 agonist treated and control groups.

Effect of GPR139 agonist on preference to the neutral compartment during fear memory recall. (A) Representative top-view video tracking of swimming behaviour in controls (a and c, 0.2% and 2% DMSO, respectively) and the fish treated with GPR139 agonist (b and d, 0.1 and 1 µg/g BW of JNJ-63533054, respectively). (B) Total time spent in the neutral context (grey compartment) during post-conditioning in controls and GPR139 agonist-treated fish. The fish treated with 0.1 µg/g BW of GPR139 agonist spent a significantly (P = 0.0477) longer time in the neutral compartment as compared to control. *, P < 0.05. n.s., no significant difference.